BridgeBio Pharma, Inc. announced the presentation of detailed positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM by Julian Gillmore, MBBS, M.D., Ph.D., FRCP, FRCPath, in a Hot Line session at the European Society of Cardiology Congress 2023.
Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam.
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023 Read More »
While some biopharma companies seek an effective and non-addictive alternative to opioids, others are looking to make opioids themselves safer.
Promising Vertex Pain Med Points to New Era for Analgesics Read More »
In the next two weeks, the FDA will hand out regulatory verdicts to BMS, Outlook Therapeutics and BioLineRx.
As the FDA’s recent rejection of Biogen and Sage’s zuranolone for major depressive disorder highlights, biopharma companies will need to tackle emerging challenges to bring more of these drugs to patients.
Opinion: Neuroactive Steroids Face Hurdles on the Path to Bigger Markets Read More »
Boston Scientific Corporation announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation.
Innovative vaccine company Recbio announced its latest progress and interim results for 2023.
Mallinckrodt plc announced that it has taken the next step to implement the comprehensive financial restructuring plan contemplated by a Restructuring Support Agreement the Company previously entered into with more than 85% of each of the Company’s first and second lien debtholders and the Opioid Master Disbursement Trust II, as announced on August 23, 2023.
On August 23rd, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. released its financial results for the first half of 2023.
A simple vista, no se aprecia nada extraño en la zona mostrada de este árbol. Puede que incluso no se note con una observación más atenta. (Imagen: Mark D. Scherz, Natural History Museum of Denmark. CC BY-SA) Pero, aunque no se note, hay algo pos …
